BIOMAT Database Logo BIOMAT Database Logo

Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia. 2009

S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Laboratoire d'hématologie moléculaire et cellulaire, institut Pasteur de Tunis, Tunis, Tunisia. samia.menif@rns.tn

The optimal management of malignant haematological disorders depend on the degree of tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for molecular detection and therapy surveillance of malignant disease since this entity was the first leukemia shown to be associated with a specific bcr-abl fusion gene in the patient's leukemia cells. Molecular monitoring of bcr-abl transcript levels by real-time quantitative PCR is increasingly used to assess treatment response in patients with chronic myeloid leukemia (CML). This has become particularly relevant in the era of imatinib therapy when residual levels of leukaemia usually fall below the level of detection by bone marrow cytogenetic analysis. We monitored bcr-abl transcript levels by quantitative real time PCR in 50 tunisian patients treated with imatinib for chronic myeloid leukemia in chronic phase for a median of 29 months (3-60) after they started imatinib.

UI MeSH Term Description Entries
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003199 Computer Systems Systems composed of a computer or computers, peripheral equipment, such as disks, printers, and terminals, and telecommunications capabilities. Computer Architecture,Computer System,Computer Systems Development,Computer Systems Evaluation,Computer Systems Organization,Real Time System,Real-Time Systems,Organization, Computer Systems,Architecture, Computer,Architectures, Computer,Computer Architectures,Computer Systems Evaluations,Development, Computer Systems,Evaluation, Computer Systems,Evaluations, Computer Systems,Real Time Systems,Real-Time System,System, Computer,System, Real Time,System, Real-Time,Systems, Computer,Systems, Real Time,Systems, Real-Time,Time System, Real,Time Systems, Real
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Alternative BCR/ABL transcripts in chronic myeloid leukemia.
October 1990, Blood,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
June 1999, Leukemia,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
January 2016, Methods in molecular biology (Clifton, N.J.),
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Residual bcr/abl transcripts in chronic myeloid leukaemia.
February 1990, Lancet (London, England),
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Detection of BCR-ABL transcripts in chronic myeloid leukaemia by nested PCR.
February 1999, Leukemia research,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
BCR-ABL-negative chronic myeloid leukemia.
May 2007, Current hematologic malignancy reports,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
May 2008, Archives of Iranian medicine,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia.
January 2011, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
BCR-ABL mutations in chronic myeloid leukemia - not only detection.
August 2008, Leukemia & lymphoma,
S Menif, and S Zarrouki, and R Jeddi, and N ben Alaya, and Z BelHadj Ali, and H Ben Abid, and S Hdeiji, and M Elloumi, and A Khlif, and B Meddeb, and K Dellagi
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.
May 1999, Leukemia,
Copied contents to your clipboard!